[Federal Register Volume 62, Number 175 (Wednesday, September 10, 1997)]
[Notices]
[Pages 47676-47677]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-23900]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: For Nucleic Acid-Based
Vaccines and Therapeutics
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a limited field of use exclusive license in the United States to
practice the invention embodied in U.S. Patent Application Number 08/
286,730 entitled, ``Liposomal Delivery System for Nucleic Acids,'' and
its Continuation-In-Part U.S. Patent Application Serial Number 08/
522,246, and all related foreign filings (PCT/US95/09867), invented by
Alain Thierry formerly of the National Cancer Institute, to Biovector
Therapeutics, S.A of Labage, France. The patent rights in these
inventions have been assigned to the United States of America.
DATES: Only written comments and/or applications for a license which
are received by NIH on or before December 9, 1997 will be considered.
ADDRESSES: Requests for copies of the subject issued patent and pending
patent applications, inquiries, comments and other materials relating
to the contemplated license should be directed to: Mr. Larry M.
Tiffany, Office of Technology Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone:
(301) 496-7056, ext. 206; Facsimile: (301) 402-0220. A signed
Confidentiality Agreement will be required to receive copies of the
pending patent applications.
SUPPLEMENTARY INFORMATION: The present invention relates to a liposome
composition comprising a bi- or multi-layered membrane surrounding an
internal aqueous liposome comprising at least one cationic
lipopolyamine and at least one neutral lipid provided in a molar ratio
range, said ratio from about .02:1 to 2:1. In addition to the pending
composition claims there are also pending rights to methods of
preparing the liposome composition, pharmaceutical compositions
including the liposome and methods of introducing nucleic acids into
cells using the liposome. This invention is advantageous over
alternative lipid preparations due to its ability to more
[[Page 47677]]
easily form liposomes at physiological temperatures and pH hence making
it potentially more stable in-vivo.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 90 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use would be limited to nucleic acid-based vaccines
and therapeutics.
Applications for a license to the field of use described in this
Notice will be treated as objections to the contemplated license.
Comments and objections will not be made available for public
inspection and, to the extent permitted by law, will not be subject to
disclosure under the Freedom of Information Act, 5 U.S.C. 552.
Dated: September 2, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-23900 Filed 9-9-97; 8:45 am]
BILLING CODE 4140-01-P
